Christopher Hunt Keir

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase

Annie Guérin, Lei Chen, Raluca Ionescu‐Ittu et al. · Current Medical Research and Opinion · 2014 · 70 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

Jörge E. Cortes, Jeffrey H. Lipton, Carole B. Miller et al. · Clinical Lymphoma Myeloma & Leukemia · 2016 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin

Kenneth Lawrence, May Adra, Christopher Hunt Keir · Journal of Infection · 2005 · 32 citations

Medicine, Neuroscience, Pharmacology +9

Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia

Alessandro Crotta, Jie Zhang, Christopher Hunt Keir · Current Medical Research and Opinion · 2017 · 31 citations

Medicine, Hematology, Pediatrics +17